Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study

被引:0
作者
Hyoung Cheol Lee
Soohyun Cho
Byung-Kun Kim
机构
[1] Eulji University School of Medicine,Department of Neurology, Nowon Eulji Medical Center
[2] Eulji University School of Medicine,Department of Neurology, Uijeongbu Eulji Medical Center
来源
Neurological Sciences | 2023年 / 44卷
关键词
Galcanezumab; Chronic migraine; Calcitonin gene-related peptide; Monoclonal antibody;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2455 / 2463
页数:8
相关论文
共 232 条
[1]  
Park JW(2018)The International Classification of Headache Disorders, 3rd edition Cephalalgia 38 1-211
[2]  
Moon HS(2014)Chronic daily headache in Korea: prevalence, clinical characteristics, medical consultation and management J Clin Neurol 10 236-243
[3]  
Kim JM(2018)Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 17 954-976
[4]  
Lee KS(2019)Migraine: epidemiology, burden, and comorbidity Neurol Clin 37 631-649
[5]  
Chu MK(2011)Migraine chronification Curr Neurol Neurosci Rep 11 139-148
[6]  
Burch RC(2011)Chronic migraine: epidemiology and disease burden Curr Pain Headache Rep 15 70-78
[7]  
Buse DC(2004)Topiramate in migraine prevention: results of a large controlled trial Arch Neurol 61 490-5
[8]  
Lipton RB(2004)Topiramate for migraine prevention: a randomized controlled trial JAMA 291 965-973
[9]  
Bigal ME(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial Cephalalgia 30 793-803
[10]  
Lipton RB(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial Cephalalgia 30 804-814